NEW YORK (GenomeWeb) – 10x Genomics said on Tuesday that it has acquired Epinomics, a startup that spun out of Stanford University to commercialize technology for mapping chromatin regions across the genome.
Epinomics has been developing its technology for clinical applications, including using epigenomic signatures to predict response to immunotherapy. It has a collaboration with Stanford's Park Institute for Cancer Immunotherapy to use biomarkers and epigenomics technology to improve cancer immunotherapies.
Privately held 10x Genomics plans to integrate Epinomics' ATAC-seq epigenetic technology onto its Chromium system and plans to launch a single-cell ATAC solution by the end of the year.
"Today's acquisition gives us a strong team, IP, and technology that has been enthusiastically validated by customers," 10x Genomics CEO Serge Saxonov said in a statement. "It provides a foundation for powerful new products and positions us well to become the leader in epigenomics."
Financial terms of the acquisition were not disclosed. Epinomics is backed by venture firms including Lightspeed Venture Partners, Felicis Ventures, and Founders Fund.